key: cord-0715909-booojguw
authors: Debelenko, Larisa; Katsyv, Igor; Chong, Alexander M.; Peruyero, Leonore; Szabolcs, Matthias; Uhlemann, Anne-Catrin
title: Trophoblast Damage with Acute and Chronic Intervillositis: Disruption of Placental Barrier by SARS-CoV-2
date: 2020-12-13
journal: Hum Pathol
DOI: 10.1016/j.humpath.2020.12.004
sha: 3daaeb01983eae0c06fa2eb60665a109d235f916
doc_id: 715909
cord_uid: booojguw

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was demonstrated in placenta; however, the data on the prevalence of placental infection and associated histopathology are limited. In order to identify the frequency and features of SARS-CoV-2 involvement we performed a clinicopathologic analysis of 75 placental cases from women infected at the time of delivery and 75 uninfected controls. Placental samples were studied with anti-SARS-CoV-2 immunohistochemistry (IHC) and/or in situ hybridization (ISH). Positive results were confirmed by electron microscopy (EM) and quantitative reverse-transcription polymerase chain reaction (qRT-PCR). During delivery only one women had symptoms of COVID-19, six women reported previous symptoms, and 68 women were asymptomatic. All neonates tested negative for SARS-CoV-2 by nasopharyngeal swab PCR. Obstetric histories were unremarkable in 29 of 75 positive and 8 of 75 negative women. Respectively, placental examination was normal in 12 of 75 infected and 3 of 75 uninfected subjects. In the remaining cases placental pathology correlated with obstetric comorbidities without significant differences between positive and negative women. SARS-CoV-2 was identified in one placenta of an infected, but asymptomatic parturient. Viral staining was predominantly localized to the syncytiotrophoblast (STB) which demonstrated marked damage accompanied by perivillous fibrin deposition and mixed intervillositis. A significant decrease of viral titers was detected in the attached umbilical cord comparing to the villous parenchyma by qRT-PCR. SARS-CoV-2 is seldom identified in placentas of infected women. Placental involvement by the virus is characterized by STB damage disrupting placental barrier and can be seen in asymptomatic mothers without evidence of vertical transmission.

First reports on placental findings in SARS-CoV-2 -infected women pointed out increased rates of features associated with maternal and fetal vascular malperfusion [1] [2] [3] . However, several recent studies attested a lack of significant differences in histopathologic characteristics between SARS-CoV-2 positive and negative women [4] [5] [6] [7] . Placental involvement associated with transmission of the virus to neonates has only been reported in a handful of cases [8] [9] [10] [11] [12] .

Approximately 88% of women who tested positive for SARS-CoV-2 by universal screening at admission for delivery in our institution have been asymptomatic [13] , and no cases of congenital infection have been diagnosed thus far. To date, it is unknown whether the virus can affect placenta and penetrate the placental barrier in the absence of clinical manifestations of maternal infection.

Here, we compared placental histopathology in conjunction with antenatal and intrapartum histories in cohorts of women who tested positive and negative for SARS-CoV-2 at the time of delivery.

We did not detect significant differences in pathological features between the groups; however, one out of 75 positive cases showed pathology attributable to SARS-CoV-2 in an asymptomatic mother.

The study was approved by the Institutional Review Board. We performed a retrospective review of placental pathology reports and slides from the files of our Pathology Department. Pertinent clinical information was extracted from medical records. We included 75 women who tested positive for SARS-CoV-2 by routine PCR-based nasopharyngeal swab on admission for labor and delivery at our Medical Center during the regional peak of the COVID-19 pandemic, from March 20 to June 15, 2020. Maternal SARS-CoV-2 PCR tests were performed within 24 hours of placental deliveries. All neonates born to mothers positive for SARS-CoV-2 were also tested by SARS-CoV-2 PCR of nasopharyngeal swabs within 12-72 hours after delivery. A control group of 75 women who tested negative was matched for gestational age and parity. Subjects with indeterminate SARS-CoV-2 PCR testing results or reversal of positive to negative testing results were excluded.

Pathology diagnoses and representative slides were re-reviewed and the findings were classified using recommendation of the Amsterdam Placental Workshop Consensus [14] .

IHC was performed on routine sections of placental disc with monoclonal antibodies against SARS-CoV-2 spike (mouse monoclonal, clone 1A9 (mAb 1A9); dilution 1:1000; GeneTex, Irvine, CA) and nucleocapsid (rabbit monoclonal, clone 0001 (mAb 001); dilution 1:5000; Sino Biological, Wayne, PA) proteins. ISH was performed using the RNAscope-ProbeV-nCoV2019-S (Advanced-Cell-Diagnostics, Hayward, CA). The assays were validated using pulmonary tissues obtained at autopsies from patients who died of COVID-19; the validation indicated equally high specificity of SARS-CoV-2 ISH and ICH with the highest sensitivity of the anti-nucleocapsid IHC.

Sixty-four placentas from infected women were studied with at least one modality, including 4 cases with ISH, 21 with anti-spike and 39 with anti-nucleocapsid IHC, and 11 placentas were studied with combinations of the above techniques, including 2 with anti-nucleocapsid antibody and ISH, 5 with antispike antibody and ISH, 3 with anti-spike and anti-nucleocapsid antibodies, and 1 case was studied with all 3 techniques. At least 3 placentas from the group of not infected women were stained with each antibody and ISH as negative controls.

The assays were carried out using Bond-III Fully Automated IHC and ISH Stainer (Leica Biosystems, Vista, CA) according to the manufacturers' recommendations.

The light microscopy images were captured using Olympus BX41 microscope, DP 26 digital camera, and cellSense imaging software (Life Science Solutions).

For the SARS-CoV-2 positive case, EM was performed on the formalin fixed paraffin embedded (FFPE) tissue of placental disc punched of paraffin block, deparaffinized and reprocessed for EM using the standard protocol for medical biopsies and scoped using the JEOL 1011 instrument (Peabody, MA).

In addition, RNA was extracted from FFPE tissue using Quick-RNA FFPE Kit (Zymo Research, Irvin, CA). Separate tissue samples of villous parenchyma, membranes and umbilical cord were obtained J o u r n a l P r e -p r o o f from paraffin blocks freshly cut with sterile blades, using 2 mm sterile disposable biopsy punches (Miltex, York, PA) to avoid cross contamination.

Quantitative RT-PCR was carried out using the SARS-CoV-2 RUO kit (Thermofisher Scientific) which targets the N1 and N2 sequences of the virus as well as RP (RNase P) for RNA control (Integrated DNA Technology, Coralville, Iowa), Taqman 4X master mix and Quant Studio 3 Real-Time PCR System (Thermofisher Scientific). Each assay included a standard curve, using the 2019-nCoV_N_Positive Control (Integrated DNA Technology, Coralville, Iowa), to estimate the viral copies in each reaction. Any sample with an exponential fluorescent curve and threshold cycle (C t ) value less than 40 is considered positive for SARS-CoV-2 as by the Center for Disease Control recommendations [15] . Viral titers were calculated as copy numbers divided by sample mass.

Statistical analysis was performed in R version 3.6.3 (R Foundation for Statistical Computing, https://www.r-project.org/foundation/). Significance of differences in counts of clinical or pathological diagnoses were compared using a one-way Chi-square goodness of fit test, and P values were adjusted for multiple comparisons using the Holm method.

Gestational ages ranged from 33 1/7 to 41 (median 38 5/7) in SARS-CoV-2 negative and 31 2/7 to 41 (median 39) in SARS-CoV-2 positive women. Four placentas were from twin pregnancies (two in each group). In the group of 75 women who were negative for SARS-CoV-2 by routine RT-PCR nasopharyngeal swabs, antenatal histories and labors were unremarkable in 8 (10.6%), compared to 29 (38.7%) women in the group of 75 positive (P =0.0005; Table 1 ). Clinical diagnoses of non-reassuring fetal heart rate (NRFHR), either remote or immediate to deliveries, or category 2 tracing were significantly more prevalent in the group of negative women (22 of 75 versus 6 of 75, P =0.002), which reflected high volumes of the placentas from high-risk pregnancies in our pathology practice. Similarly, clinical diagnoses of preeclampsia (PEC) and intrauterine growth restriction (IUGR) were more prevalent J o u r n a l P r e -p r o o f among negative women, but the differences were not significant (Table 1) . Neonatal congenital anomalies were more frequently seen in non-infected high-risk deliveries and one case of intrauterine fetal demise due to a cord accident (tight nuchal cord) was diagnosed in the group of uninfected women.

The pathological findings of maternal vascular malperfusion including decidual arteriopathy, distal villous hypoplasia and hypermaturity, and large infarctions were more frequently observed in the group of negative women ( Table 2 ). Decidual arteriopathy was seen in one of 75 positive women in association with PEC with severe features. Three additional cases showed chronic features of maternal vascular malperfusion (distal villous hypoplasia and villous hypermaturity) in infected women, and these findings also correlated with the clinical diagnosis of PEC. Similarly, IUGR and NRFHR correlated with morphologic features of fetal vascular malperfusion (FVM), which were more frequently diagnosed in the group of negative women (Table 2 ). While the frequencies of chronic inflammatory lesions were practically equal between the groups, chronic lymphoplasmacytic deciduitis was more prevalent in the group of SARS-CoV-SARS-CoV-2 immunohistochemistry with anti-spike or anti-nucleocapsid antibodies and in situ hybridization were negative in 74 of 75 placentas of infected and in all stained placentas of uninfected women. The detailed clinicopathologic features of the positive placental case are presented below.

A 33 year old gravida 3 para 2 presented in labor at 37 weeks of gestation. Her prenatal course was significant for a diet-controlled gestational diabetes (glucose challenge test 178 mg/dL, glucose tolerance test 185/201/181, HbA1c 5.5%). At admission she tested positive for SARS-CoV-2 by a routine swab PCR-based test but was asymptomatic and did not require supplemental oxygen. Complete blood count (CBC) was unremarkable except for thrombocytopenia (platelets 112 x 10 3 /µL, normal range 167-374 x 10 3 /µL); and decreased monocytes (2%, normal range 4-8%). Additional work up revealed mildly elevated inflammatory markers, including C-reactive protein (39.54 mg/L, normal range 0.00-10.00 mg/L) and erythrocyte sedimentation rate (52 mm/hr, normal range 0-20 mm/hr), as well as increased lactate dehydrogenase (251 U/L, normal range 135-214 U/L) and D-Dimer (1.34 µg/mL, normal range 0.00 -0.80 µg/mL). Interleukin-6 was within normal limits.

She did not receive any treatment for her asymptomatic SARS-CoV-2 infection and gave birth to a healthy baby-girl by a precipitous uncomplicated vaginal delivery. The patient was advised on appropriate infection control precautions while taking care of the baby and breastfeeding.

The baby's birth weight was 2410 g (in 50 percentile) and Apgar scores were 9 and 9 at 1 and 5 min, respectively. The girl was healthy looking, vigorous and passed all standard newborn screens (vital signs, bilirubin, congenital heart disease and hearing). The neonatal SARS-CoV-2 nasal swab test performed on day 2 postpartum was negative. Viral serology tests were not available at the time.

The mother and the child were discharged on hospital day 2 in good health. Maternal and neonatal health evaluations performed by telephone and video assessments on postpartum days three, four, six and 40 were unremarkable.

Debelenko et al -8

The gross examination showed a soft yellow-white lesion located under the chorionic plate, occupying approximately 5% of the fetal surface. At low magnification, scattered and confluent lesions were seen in each of the four studied sections in a predominantly subchorionic distribution. Individual lesions involved from several to hundreds of villi each and cumulatively affected approximately 15% of the disc. The lesions were characterized by perivillous fibrin deposition and mild to moderate intervillous inflammation ( Figure 1A ). The inflammatory infiltrate was patchy and composed of monocytes/macrophages, neutrophils, and rare lymphocytes ( Figure 1B Figure 1F ). Only rare nodular intravillous fibrin ( Figure 1E) and no significant thrombosis of villous capillaries was observed. The umbilical cord, decidua and membranes were histologically unremarkable.

In summary, the lesions were patchy, focally confluent, and at low magnification resembled villous agglutination with perivillous fibrin deposition. A differential diagnosis of acute ischemia/early infarctions was considered, taking into account marked cellular injury of STB. However, mixed intervillous infiltrate was in favor of an inflammatory and possibly infectious etiology.

J o u r n a l P r e -p r o o f Immunohistochemistry with anti-spike mAb 1A9 showed a strong diffuse and granular staining of STB in a patchy distribution (Figure 2A) . ISH with the probe against the spike protein yielded similar, albeit weaker, results ( Figure 2B ). In these two assays, which targeted the spike protein, the staining signal was limited to the villous trophoblast and a subset of maternal mononuclear cells in intervillous spaces.

Immunohistochemistry with anti-nucleocapsid antibody mAb 0001 showed strong patchy staining which included mononuclear blood cells in maternal circulation, STB as well as the villous stroma ( Figure   2C ) [3] . At the same time, no characteristic histopathology was found in 19 placentas of infected women, including 2 cases where the virus was identified by IHC and ISH by Hecht et al [5] . Three recent retrospective analyses also did not find detectable histomorphologic features distinguishing placentas of infected and uninfected women, regardless of experienced symptoms of infection [4, 6, 7] , including two cases positive for SARS-CoV-2 by ISH [7] .

We observed statistically not significant increases in frequencies of histopathologies associated with maternal and fetal vascular malperfusion in the group of SARS-CoV-2 negative women in correlation with higher rates of PEC, IUGR and NRFHT in this group. We explain these findings by sampling bias, since only high-risk placentas (approximately 30% of all deliveries in our hospital) are usually submitted for histopathological examination, while a higher percentage (approximately 80%) of SARS-CoV-2 J o u r n a l P r e -p r o o f positive cases were considered high risk and sent to pathology regardless of the underlying gestational morbidity during the peak of the COVID-19 pandemic in New York City. Interestingly, the negative correlation between PEC and NRFHT and COVID-19 was also noted by Zhang et al [7] . This underscores limitations inherent in the methodology of retrospective analysis likely responsible for the conflicting literature results on the overall placental pathology in SARS-CoV-2. A prospective cohort design with the 3d trimester enrolment and risk stratification might more definitively answer the question whether infection with SARS-CoV-2 increases the incidence of vascular pathology in placenta.

Our study, however, identified a rare case of placental involvement by SARS-CoV-2 and similarly to several other reported cases [8] [9] [10] [11] [12] it was associated with intervillositis. In our case the intervillositis was composed of mixed inflammatory infiltrate, but otherwise had features classically described in massive chronic intervillositis (MHI) or chronic histiocytic intervillosistis (CHI): namely, marked intervillous inflammation, intervillous fibrin, and trophoblast necrosis [17, 18] . Although in most of the cases this pathology has been associated with allo-or autoimmune dysregulations resulting in intrauterine growth restriction and recurrent reproductive loss [19, 20] , in a small subset of cases, MCI/CHI has infectious etiologies, such as malaria [21] and CMV [22] . While non-infectious MCI/CHI is composed of almost exclusively histiocytes and lymphocytes, intervillositis in infections, such as Chlamydia, Listeria, tularemia, and others, is characterized by a mixed inflammatory infiltrate [20] . The presence of neutrophils may provide a useful diagnostic clue, allowing to suspect infection as a cause of MCI/CHI. Intervillous fibrin and trophoblast necrosis, originally described in MCI/CHI, were prominent in our case of SARS-CoV-2 intervillositis and likely related to the direct injury of STB by SARS-CoV-2. In this respect the MCI/CHI in SARS-CoV-2 is similar to the diffuse alveolar damage (DAD), in which the virus directly affects alveolar epithelium leading to the exposure on the injured cellular surfaces factors promoting fibrin accumulation. Similar to DAD, the histopathological features of MCI/CHI in SARS-CoV-2 infection are not indicative of the etiology and only IHC and/or ISH can provide the specific diagnosis.

Direct involvement of STB by SARS-CoV-2 was unexpected, since CMV and Zika virus, best known to affect placenta, are localized to the villous stroma and Hofbauer cells, respectively [22, 23] , while J o u r n a l P r e -p r o o f rubella, influenza and HSV, seldom detected in placental tissue, have been demonstrated in capillary endothelium and basal plate (rubella) [24] , Hofbauer cells and cytotrophoblast (influenza) [25] , and maternal decidualized cells of decidua capsularis (HSV) [26] . Only in few infections, namely: Coxsackie virus [27] , Ebola virus [28] , and Chlamydia [29] , has STB involvement been shown. While data on the levels of constitutive expression of trophoblastic ACE-2 and TMPRSS2 receptors mediating the SARS-CoV-2 cellular entry have been controversial [30, 31] , our positive case demonstrates that the virus is capable of attaching to and destroying STA.

It has been proposed that detection of the virus in placental villous tissue signifies intrauterine transplacental transmission which should be distinguished from intrauterine vertical transmission, defined by positive RT-PCR testing of neonates for the virus at or shortly after birth, early onset of symptoms in neonates, and elevated levels of specific IgM antibodies following delivery [32] . Thus, according to these criteria, our case exemplifies an intrauterine transplacental transmission in the absence of intrauterine vertical transmission, since the neonate was healthy and negative for SARS-CoV-2 by PCR.

Although a vast majority of placentas of infected women have been studied with SARS-CoV-2 IHC and ISH in our institution, only 1 of 126 cases (75 reported here and 51 reported previously [3] ) was positive for the virus. Similarly, only rare instances of placental infection were detected by others [5, 7] .

According to some published and our preliminary data a higher rate of viral infection is detectable in placental tissue by a more sensitive qRT-PCR analysis, which, however, has limitations since it cannot differentiate between maternal viremia and viral invasion of the villous tissue.

It would be compelling to hypothesize that transplacental transmission may be associated with hypervirulent SARS-CoV-2 strains; however, Hosier et al [9] performed the whole genome sequence comparisons to global isolates and did not find viral mutations in their case of SARS-CoV-2 affected placenta. Some women may also be more susceptible to STB invasion due to individual genetic polymorphisms regulating cellular entry or cellular defenses. We, however, favor that the viral invasion in the placenta follows the pattern described in the lungs, where the virus was detectable in the alveolar epithelium only during the narrow temporal window of the acute stage of DAD and was cleared off in the organizing DAD [33] . The duration of SARS-CoV-2 infection is 20 days on average, ranging from 5 to 60 J o u r n a l P r e -p r o o f days [34] . It may therefore be possible that if the virus reaches and affects placenta prior to delivery, it can be cleared and no longer be detectable in a placental specimen obtained at childbirth. Further studies are needed to elucidate the dynamics of SARS-CoV-2 feto-maternal infection.

Unlike in the previously reported SAR-CoV-2 positive placentas [5, [7] [8] [9] [10] [11] [12] , in our case the SARS-CoV-2 transplacental infection was detected in a patient asymptomatic for COVID-19 and did not result in vertical transmission despite the marked STB damage and high placental viral qRT-PCR titers. It is possible that the premature precipitous delivery prevented further spread of the infection to the infant.

However, we also detected significant (in 5 orders of magnitude) decrease of the viral titers in the attached umbilical cord comparing to the villous parenchyma; this supports the overall pervasiveness of the placental barrier and suggests that molecular mechanisms shown to govern resistance and antiviral activity of trophoblast [35] likely play a role in protecting offspring against SARS-CoV-2.

Vascular placental pathology seen in placentas of SARS-CoV-2 positive women is largely associated with preexisting maternal and fetal conditions with no increased rates of decidual arteriopathy or fetal vasoocclusive lesions in infected women comparing to uninfected. SARS-CoV-2 can be identified in placental tissue in extremely rare cases, where the viral particles carried by maternal macrophages attach to and destroy the villous trophoblast, causing acute and chronic intervillositis, similarly to some other placental infections. This SARS-CoV-2 placental pathology can be detected in asymptomatic women while focal penetration of the placental barrier is not always associated with transmission of the infection to offspring.

The authors thank Rachel Tucker for the help with specimen sampling and PTAH special stain, and Zhimin Yu for the help with EM. Reactions for all samples were run in triplicates with consistent results. C t -cycle threshold: reflects the number of PCR cycles before the beginning of the exponential phase of the amplification curve. The lower the C t value, the higher the quantity of the target template in the sample. RP C t -C t values of the control RNase P primer/probe set. C t of included viral controls were also obtained (not shown) and along with the standard curve generated in each reaction were used for viral copy calculations. *FFPE tissue samples were punched out the paraffin block and weighted, after removal of excess paraffin and before RNA extraction.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

This research did not receive any specific grant from funding agencies in the public, commercial, or notfor-profit sectors

Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings

Placental Pathology in COVID-19

Third trimester placentas of SARS-CoV-2-positive women: Histomorphology, including viral immunohistochemistry and in situ hybridization

Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women

SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

Histopathological evaluation of placentas after diagnosis of maternal SARS-CoV-2 infection

Detection of severe acute respiratory syndrome coronavirus 2 in placentas with pathology and vertical transmission

Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth

SARS-CoV-2 infection of the placenta

Intrauterine transmission of SARS-CoV-2 infection in preterm infant

Transplacental transmission of SARS-CoV-2 infection

Placental SARS-CoV-2 in a pregnant woman with mild COVID-19 disease

Universal screening for SARS-CoV-2 in women admitted for delivery

Sampling and definitions of placental lesions: Amsterdam Placental Workshop Group Consensus Statement

US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2

Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections

Fibrinoid and trophoblastic necrosis with massive chronic intervillositis: an extreme variant of villitis of unknown etiology

Chronic intervillositis of the placenta

Massive chronic intervillositis associated with recurrent abortions

Placental pathologic lesions with a significant recurrence risk -what not to miss!

Massive chronic intervillositis of the placenta associated with malaria infection

Chronic histiocytic intervillositis with cytomegalovirus placentitis in a case of hydrops fetalis

Viral infection, proliferation, and hyperplasia of Hofbauer cells and absence of inflammation characterize the placental pathology of fetuses with congenital Zika virus infection

Immunolocalization and distribution of rubella antigen in fatal congenital rubella syndrome

H5N1 infection of the respiratory tract and beyond: a molecular pathology study

Herpes simplex virus infection of the placenta. The role of molecular pathology in the diagnosis of viral infection of placental-associated tissues

Correlation of in situ detection of infectious agents in the placenta with neonatal outcome

Ebola virus disease in pregnancy: clinical, histopathologic, and immunohistochemical findings

Chlamydia trachomatis detected in human placenta

The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study

Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?

Confirming vertical fetal infection with COVID-19: neonatal and pathology criteria for early onset and transplacental transmission of SARS-CoV-2 from infected pregnant mothers

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Duration of SARS-CoV-2 viral shedding during COVID-19 infection

The placenta as a barrier to viral infections